Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.

TitleGermline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
Publication TypeJournal Article
Year of Publication2016
AuthorsLheureux, S, Karakasis, K, Harter, P, Scott, C, Bacon, M, Bryce, J, Le Fur, N, Pujade-Lauraine, E, Oza, AM
JournalGynecol Oncol
Volume140
Start Page90
Issue1
Pagination94
Date Published01/2016
ISSN1095-6859
KeywordsBRCA1, BRCA2, ovarian
Abstract

PURPOSE: Given the implications for clinical care and prevention in identifying a BRCA1/2 mutation, the objective of this study was to determine current BRCA1/2 testing practices in ovarian cancer and to identify future directions.METHODS: Two parallel complementary web-based surveys were sent by email to representatives of Gynecologic Cancer InterGroup (GCIG) and to referral centers in countries with and without GCIG membership. Questions posed addressed indications of BRCA1/2 testing for ovarian cancer; the implication of genetic counseling; and prevention strategies employed.RESULTS: Among the GCIG, 22 collaborative groups from 19 countries answered the survey. For the complementary survey, 22 referral centers replied. Findings show criteria to offer germline BRCA1/2 testing are mixed; 55% of GCIG members based testing decisions on histology and, among all respondents the main testing criterion remains family history. Typically, genetic counseling is scheduled prior to the genetic testing; however, if negative, results may not be communicated by the genetic counselor. Time between testing and communicating results varies widely between the groups. Lastly, recommendations to relatives regarding risk reduction surgery are inconsistent.CONCLUSION: Our study highlights the need for collaborative efforts to devise international guidelines around BRCA1/2 testing in ovarian cancer to ensure consistent BRCA1/2 screening practices are adopted. Clinical practice is evolving rapidly and as BRCA1/2 testing is expected to become more widespread, new approaches are required. Coordinating BRCA1/2 testing practices is crucial in terms of care for the patient diagnosed with ovarian cancer but also towards cancer prevention for affected family members.

DOI10.1016/j.ygyno.2015.10.010
Alternate JournalGynecol. Oncol.
PubMed ID26475959